About Cellumen
Cellumen is a Healthcare company based in Pittsburgh (United States) founded in 2004, and was acquired by Apredica in August 2010. Systems biology solutions for drug safety and efficacy are provided. Cellumen has raised $11.43 million across 11 funding rounds from investors including Safeguard Scientifics, Novitas Capital and Apredica. Cellumen offers products and services including Assay Kits, Antibodies, ELISA Kits, Total Protein Assay Kit, and DNA Testing Products. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and In SIlico Assays. Its competitors include PointCross, IOTA Pharma and Conifer Point; 1 of its 3 listed competitors has raised funding.
Company details
Cellumen, acquired by Cyprotex (formerly Apredica) in 2010, was a company offering proprietary cellular systems biology-based solutions for in vitro discovery and toxicology testing of drug candidates. The company had IP w.r.t reagents and multiplexed assays using the High Content Screening platform. The company offered drug discovery and toxicology screening services and was working with immortalised HepG2 human cell lines, primary rat hepatocytes and cardiac cell lines. At the core of Cellumens expertise was its CellCiphr toxicity risk assessment technology. The company had developed CellCiphr profiles by screening a library of compounds and characterising them. These were used to identify and screen potentially toxic compounds at a much earlier stage in the drug discovery process. The company claimed that it could demonstrate savings of up to USD 91Myear for any big pharma company by applying their CellCiphr filter at the start of the hit-to-lead phase.
- Headquarters Pittsburgh, United States
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website cellumen.com
- Social LinkedIn
- Acquired by Apredica (Aug 2010)
- Total Equity Funding$11.43M (USD)
in 11 rounds
- Latest Funding Round$248.45K (USD), Series B
Mar 2010
- InvestorsSafeguard Scientifics
& 2 more
- Acquired byApredica
(Aug 2010)
Products & Services of Cellumen
Cellumen offers a comprehensive portfolio of products and services, including Assay Kits, Antibodies, ELISA Kits, Total Protein Assay Kit, and DNA Testing Products.
Kits for detecting biomolecules in biological samples
Proteins used for identifying specific antigens in research
Kits for enzyme-linked assays in protein detection
Kit for quantifying proteins in serum and tissues
Products for DNA analysis and templates in experiments
Funding Insights of Cellumen
Cellumen has successfully raised a total of $11.43M across 11 strategic funding rounds. The most recent funding activity was a Series B round of $248.45 thousand completed in March 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.43M
- Total Rounds 11
- Last Round Series B — $248,453
- First Round $20,000
(Jun 2004)
- Investors Count 2
Latest 10 of 11 funding rounds of Cellumen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2010 | $248,453 | Series B | – | – | – |
| Nov 2009 | $694,272 | Series B | – | – | – |
| May 2009 | $621,758 | Series B | – | – | – |
| Jul 2007 | $8.84M | Series B | – | – | |
| Aug 2006 | $300,000 | Debt – Convertible | – | – | – |
| May 2006 | $35,000 | Debt – Convertible | – | – | – |
| Mar 2006 | $100,000 | Debt – Convertible | – | – | – |
| Aug 2005 | $200,000 | Debt – Convertible | – | – | – |
| Jun 2005 | $1M | Series A | – | – | |
| Apr 2005 | $100,000 | Debt – Convertible | – | – | – |
3 investors in total: 3 institutional.
Investors in Cellumen
Cellumen has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Safeguard Scientifics, Novitas Capital and Apredica.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in early and growth stage companies | 1953 | safeguard.com | Radnor, United States | |
| novitascapital.com | ||||
Content on research ethics is shared by Apredica. | apredica.com |
Investor details for Cellumen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cellumen
4 dated milestones of Cellumen across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Cellumen is founded.
- Funding First funding round of $20K.
- Funding Latest funding round, Series B, of $248K.
- Exit Acquired by Apredica.
Competitors of Cellumen
Cellumen has 3 listed competitors in our database, 1 of them funded. They include PointCross, IOTA Pharma and Conifer Point.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pointcrosslifesciences.com | 2000 | Foster, United States | $120,000 | Big data platform & desktop software for preclinical & clinical research & regulatory applications | ||
| iotapharma.com | 2007 | Cambridge, United States | Offers fragment-based drug discovery products and services. | |||
| coniferpoint.com | 2015 | Doylestown, United States | New drugs are developed using custom fragment-based design software. |
Detailed competitors of Cellumen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Cellumen (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cellumen
Cellumen was founded in 2004.
Cellumen is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Cellumen is a funded company, having raised a total of $11.43M across 11 funding rounds to date. The company's 1st funding round was a Debt – Convertible of $100K, raised on Jun 2004.
Cellumen, acquired by Cyprotex (formerly Apredica) in 2010, was a company offering proprietary cellular systems biology-based solutions for in vitro discovery and toxicology testing of drug candidates. The company had IP w.r.t reagents and multiplexed assays using the High Content Screening platform. The company offered drug discovery and toxicology screening services and was working with immortalised HepG2 human cell lines, primary rat hepatocytes and cardiac cell lines. At the core of Cellumens expertise was its CellCiphr toxicity risk assessment technology. The company had developed CellCiphr profiles by screening a library of compounds and characterising them. These were used to identify and screen potentially toxic compounds at a much earlier stage in the drug discovery process. The company claimed that it could demonstrate savings of up to USD 91Myear for any big pharma company by applying their CellCiphr filter at the start of the hit-to-lead phase.
Cellumen's top competitors include PointCross, Conifer Point and IOTA Pharma.
Cellumen offers Assay Kits, Antibodies, ELISA Kits, Total Protein Assay Kit, and DNA Testing Products.
Cellumen has 3 investors. Key investors include Safeguard Scientifics, Novitas Capital, and Apredica.
Yes. Cellumen was acquired by Apredica in August 2010.